Ting Wang1, Yasuhiro Takikawa, Takumi Satoh, Yoshichika Yoshioka, Kunio Kosaka, Yoshinori Tatemichi, Kazuyuki Suzuki. 1. Department of Gastroenterology and Hepatology, Iwate Medical University Department of Welfare Engineering, Faculty of Engineering, Iwate University Department of Pathology, Iwate Medical University School of Medicine, Morioka Immunology Frontier Research Center, Osaka University, Osaka Research and Development Center, Nagase, Tokyo, Japan.
Abstract
AIM: Carnosic acid (CA) inhibits adipogenesis in vitro. The present study evaluated the therapeutic effects of CA in ob/ob mice. METHODS: The experimental animals were given a standard chow diet with or without CA for 5 weeks. Bodyweight gain and food intake were measured during this period. Magnetic resonance imaging analysis, histological examination, serum chemistry analysis and intraperitoneal glucose tolerance test (IPGTT) were all performed. RESULTS: The mice fed CA experienced significant weight loss and reduced visceral adiposity, in addition to significantly reduced serum triglyceride (TG) and cholesterol levels. Importantly, CA had a dramatic effect on the liver by reducing the hepatic TG content, thus decreasing serum alanine aminotransferase levels. In addition, IPGTT revealed that CA significantly improved glucose tolerance. CONCLUSION: These data suggest that CA is a novel therapeutic agent for obesity-related non-alcoholic fatty liver disease.
AIM: Carnosic acid (CA) inhibits adipogenesis in vitro. The present study evaluated the therapeutic effects of CA in ob/ob mice. METHODS: The experimental animals were given a standard chow diet with or without CA for 5 weeks. Bodyweight gain and food intake were measured during this period. Magnetic resonance imaging analysis, histological examination, serum chemistry analysis and intraperitoneal glucose tolerance test (IPGTT) were all performed. RESULTS: The mice fed CA experienced significant weight loss and reduced visceral adiposity, in addition to significantly reduced serum triglyceride (TG) and cholesterol levels. Importantly, CA had a dramatic effect on the liver by reducing the hepatic TG content, thus decreasing serum alanine aminotransferase levels. In addition, IPGTT revealed that CA significantly improved glucose tolerance. CONCLUSION: These data suggest that CA is a novel therapeutic agent for obesity-related non-alcoholic fatty liver disease.
Authors: María Romo Vaquero; María-Josefa Yáñez-Gascón; Rocío García Villalba; Mar Larrosa; Emilie Fromentin; Alvin Ibarra; Marc Roller; Francisco Tomás-Barberán; Juan Carlos Espín de Gea; María-Teresa García-Conesa Journal: PLoS One Date: 2012-06-22 Impact factor: 3.240